Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications today announced the successful completion of a $29 million Series B financing. The financing was led by Sorrento Therapeutics with participation from existing investors including Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega. The Foundation for Prader-Willi Research also participated as an investor in Series B.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion. Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: 2017
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Aardvark Therapeutics